Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 12/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782254 | 0.86 | ALDH1A1 (0.56) | HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1781314 | 0.83 | SCD (0.55) | GBA1 | |
| SCHEMBL1783905 | 0.83 | MEN1 (0.55) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10722320 | 0.78 | HTT (0.89) | HTTALDH1A1 | |
| SCHEMBL1780863 | 0.77 | MAPT (0.41) | HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1780586 | 0.75 | HCRTR1 (0.47) | HTTGBA1 | |
| SCHEMBL1780680 | 0.75 | HCRTR1 (0.47) | HTTGBA1SMN1; SMN2 | |
| SCHEMBL1783515 | 0.75 | TP53 (0.46) | HTTGBA1LMNASMN1; SMN2 | |
| SCHEMBL4548030 | 0.75 | HTT (0.77) | HTTALDH1A1 | |
| SCHEMBL1781717 | 0.74 | POLB (0.55) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-8618287-B2 | Derivatives of triazines and uracils, their preparation and their application in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | UNG, TYMS, UMPS | HTT 1465/4885ALDH1A1 390/4885GBA1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.